Lv2
145 积分 2021-04-26 加入
Epigenetic regulation of Cereblon in cancer: molecular mechanisms and clinical implications
20小时前
待确认
Pan-RAS inhibitor daraxonrasib shows promise in pancreatic cancer
2天前
已完结
Contemporary design of small-molecule kinase modulators: orthosteric, allosteric and induced-proximity strategies
8天前
已完结
Safety considerations for cereblon-recruiting targeted protein degraders
8天前
已完结
The evolving landscape of CDK inhibitor use in breast cancer therapy and beyond
9天前
已完结
Daraxonrasib in Previously Treated Advanced RAS -Mutated Pancreatic Cancer
12天前
已完结
Daraxonrasib in Previously Treated Advanced RAS -Mutated Pancreatic Cancer
13天前
已完结
Daraxonrasib in Previously Treated Advanced RAS -Mutated Pancreatic Cancer
13天前
已完结
Lessons learned in linking PROTACs from discovery to the clinic
22天前
已完结
Efficacy and safety signals from early-phase studies of KRAS inhibition in pancreatic cancer
1个月前
已完结
皖公网安备34019202002308
